Stephen Senn

List of Publications by Year
in descending order

Version: 2024-02-01

219 papers	11,141 citations	66343 42 h-index	38395 95 g-index
299 all docs	299 docs citations	299 times ranked	12175 citing authors

#	Article	IF	Citations
1	Empirical studies of balance do not justify aÂrequirement for 1,000 patients per trial. Journal of Clinical Epidemiology, 2022, 148, 184-188.	5.0	1
2	Ten simple rules for good research practice. PLoS Computational Biology, 2022, 18, e1010139.	3.2	12
3	The design and analysis of vaccine trials for <scp>COVID</scp> â€19 for the purpose of estimating efficacy. Pharmaceutical Statistics, 2022, 21, 790-807.	1.3	4
4	<scp>Viewpoint</scp> : Do not resurrect the twoâ€stage procedure. Pharmaceutical Statistics, 2022, 21, 808-814.	1.3	0
5	Implementing Historical Controls in Oncology Trials. Oncologist, 2021, 26, e859-e862.	3.7	12
6	Stephen Sennâ€™s contribution to the Discussion of â€˜Testing by betting: A strategy for statistical and scientific communicationâ€™ by Glenn Shafer. Journal of the Royal Statistical Society Series A: Statistics in Society, 2021, 184, 459-460.	1.1	0
7	The statistical properties of RCTs and a proposal for shrinkage. Statistics in Medicine, 2021, 40, 6107-6117.	1.6	18
8	The outstanding scientist, R.A. Fisher: his views on eugenics and race. Heredity, 2021, 126, 565-576.	2.6	6
9	Giving and taking: ethical treatment assignment in controlled trials. Journal of the Royal Society of Medicine, 2021, 114, 525-530.	2.0	1
10	Clustered allocation as a way of understanding historical controls: Components of variation and regulatory considerations. Statistical Methods in Medical Research, 2020, 29, 1960-1971.	1.5	11
11	Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. Clinical Pharmacology and Therapeutics, 2019, 106, 204-210.	4.7	24
12	Treatment Effects in Multicenter Randomized Clinical Trials. JAMA - Journal of the American Medical Association, 2019, 321, 1211.	7.4	8
13	John Ashworth Nelder. 8 October 1924â€”7 August 2010. Biographical Memoirs of Fellows of the Royal Society, 2019, 67, 307-326.	0.1	0
14	Random main effects of treatment: A case study with a network metaâ€analysis. Biometrical Journal, 2019, 61, 379-390.	1.0	8
15	Sample size considerations for n-of-1 trials. Statistical Methods in Medical Research, 2019, 28, 372-383.	1.5	43
16	Childhood asthma exacerbations and ADRB2 polymorphism: Caution is needed. Journal of Allergy and Clinical Immunology, 2018, 141, 1954-1955.	2.9	3
17	Statistical pitfalls of personalized medicine. Nature, 2018, 563, 619-621.	27.8	129
18	Lessons learned from IDeAl â€” 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases, 2018, 13, 77.	2.7	22

#	Article	IF	Citations
19	Statistical Analysis Plans for Clinical Trialsâ€"Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1938.	7.4	0
20	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 2018, 7, 30.	1.6	17
21	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 2018, 7, 30.	1.6	14
22	Statistical issues in firstâ€inâ€human studies on BIA 10â€2474: Neglected comparison of protocol against practice. Pharmaceutical Statistics, 2017, 16, 100-106.	1.3	11
23	Contribution to the discussion of â€˜â€œA critical evaluation of the current pâ€value controversyâ€â€™. Biometrical Journal, 2017, 59, 892-894.	1.0	3
24	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	6.4	24
25	Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA - Journal of the American Medical Association, 2017, 318, 2337.	7.4	290
26	Cushny and Peebles, optical isomers and the birth of modern statistics. Journal of the Royal Society of Medicine, 2017, 110, 501-502.	2.0	0
27	Mastering variation: variance components and personalised medicine. Statistics in Medicine, 2016, 35, 966-977.	1.6	143
28	A Chronicle of Permutation Statistical Methods: 1920â€“2000, and Beyond, by K J Berry, J E Johnston, and P J W Mielke. Bulletin of the British Society for the History of Mathematics, 2016, 31, 155-156.	0.1	1
29	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology, 2016, 31, 337-350.	5.7	1,761
30	Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. Pain, 2016, 157, 2544-2551.	4.2	16
31	Understanding Variation in Sets of N-of-1 Trials. PLoS ONE, 2016, 11, e0167167.	2.5	59
32	Individual response to exercise training - a statistical perspective. Journal of Applied Physiology, 2015, 118, 1450-1459.	2.5	204
33	Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery, 2015, 14, 219-221.	46.4	12
34	Various varying variances: The challenge of nuisance parameters to the practising biostatistician. Statistical Methods in Medical Research, 2015, 24, 403-419.	1.5	22
35	R&D productivity rides again?. Pharmaceutical Statistics, 2015, 14, 1-3.	1.3	20
36	Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committeeâ€"adolescentsâ€™ melanoma as a paradigm. Pharmaceutical Statistics, 2014, 13, 211-213.	1.3	18

#	Article	IF	Citations
37	A note regarding â€˜random effectsâ€™. Statistics in Medicine, 2014, 33, 2876-2877.	1.6	18
38	Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment. Pain, 2014, 155, 457-460.	4.2	33
39	A note regarding Lee's checks for minimum numbers of subjects where relative risks have been calculated. Statistics in Medicine, 2014, 33, 4135-4138.	1.6	0
40	Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain, 2014, 155, 1683-1695.	4.2	99
41	A note regarding metaâ€analysis of sequential trials with stopping for efficacy. Pharmaceutical Statistics, 2014, 13, 371-375.	1.3	7
42	Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials. Drugs in R and D, 2013, 13, 9-16.	2.2	28
43	Comment on Gelman and Shalizi. British Journal of Mathematical and Statistical Psychology, 2013, 66, 65-67.	1.4	22
44	Issues in performing a network meta-analysis. Statistical Methods in Medical Research, 2013, 22, 169-189.	1.5	62
45	A Brief Note Regarding Randomization. Perspectives in Biology and Medicine, 2013, 56, 452-453.	0.5	2
46	Some issues in predicting patient recruitment in multiâ€centre clinical trials. Statistics in Medicine, 2013, 32, 5458-5468.	1.6	21
47	Invalid inversion. Significance, 2013, 10, 40-42.	0.4	6
48	Seven myths of randomisation in clinical trials. Statistics in Medicine, 2013, 32, 1439-1450.	1.6	177
49	Being Efficient About Efficacy Estimation. Statistics in Biopharmaceutical Research, 2013, 5, 204-210.	0.8	10
50	Bad karma. Medical Writing, 2013, 22, 252-255.	0.1	1
51	Authors are also reviewers: problems in assigning cause for missing negative studies. F1000Research, 2013, 2, 17.	1.6	5
52	What does randomisation achieve?. Evidence-Based Medicine, 2012, 17, 1-2.	0.6	11
53	Tea for Three: Of Infusions and Inferences and Milk in First. Significance, 2012, 9, 30-33.	0.4	26
54	The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation. Statistics in Medicine, 2012, 31, 4280-4295.	1.6	30

#	Article	IF	Citations
55	Misunderstanding publication bias: editors are not blameless after all. F1000Research, 2012, 1, 59.	1.6	12
56	Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2012, 7, e38273.	2.5	26
57	P-Values. , 2012, , 940-948.		0
58	Crossover Design. , 2012, , 380-385.		0
59	U is for Unease: Reasons for Mistrusting Overlap Measures for Reporting Clinical Trials. Statistics in Biopharmaceutical Research, 2011, 3, 302-309.	0.8	13
60	Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds â€"Gastrointestinal Adverse Effects. Drugs in R and D, 2011, 11, 277-288.	2.2	38
61	BMJ tackles FDA's mote in eye while ignoring own beam. BMJ: British Medical Journal, 2011, 343, d5614-d5614.	2.3	0
62	Francis Galton and Regression to the Mean. Significance, 2011, 8, 124-126.	0.4	32
63	Review of Fleiss, statistical methods for rates and proportions. Research Synthesis Methods, 2011, 2, 221-222.	8.7	35
64	Creating a suite of macros for meta-analysis in SASÂ®: A case study in collaboration. Statistics and Probability Letters, 2011, 81, 842-851.	0.7	17
65	Investigating variability in patient response to treatment â€“ a case study from a replicate cross-over study. Statistical Methods in Medical Research, 2011, 20, 657-666.	1.5	46
66	Hans van Houwelingen and the Art of Summing up. Biometrical Journal, 2010, 52, 85-94.	1.0	49
67	Comparisons of minimization and Atkinson's algorithm. Statistics in Medicine, 2010, 29, 721-730.	1.6	26
68	Planning and analysis of crossâ€over trials in infertility. Statistics in Medicine, 2010, 29, 3203-3210.	1.6	20
69	Significant errors. Lancet, The, 2010, 376, 1390-1391.	13.7	1
70	Crossover Design. , 2010, , 380-385.		2
71	P-Values. , 2010, , 940-948.		0
72	Adverse Gastrointestinal Effects of Brief Use of Full Strength, OTC Aspirin in Randomized Clinical Trials: A Meta-Analysis. American Journal of Gastroenterology, 2010, 105, S393.	0.4	0

#	Article	IF	Citations
73	Placebo Misconceptions. American Journal of Bioethics, 2009, 9, 53-54.	0.9	8
74	Overstating the evidence â€“ double counting in meta-analysis and related problems. BMC Medical Research Methodology, 2009, 9, 10.	3.1	134
75	Measurement in clinical trials: A neglected issue for statisticians?. Statistics in Medicine, 2009, 28, 3189-3209.	1.6	115
76	Authors' Rejoinder to Commentaries on â€˜Measurement in clinical trials: A neglected issue for statisticians?â€™. Statistics in Medicine, 2009, 28, 3223-3225.	1.6	0
77	Commentary on â€˜Designs for doseâ€“escalation trials with quantitative responsesâ€™. Statistics in Medicine, 2009, 28, 3754-3758.	1.6	7
78	Lessons from TGN1412 and TARGET: implications for observational studies and metaâ€•analysis. Pharmaceutical Statistics, 2008, 7, 294-301.	1.3	17
79	Statisticians and evidence â€“ mote and beam. Pharmaceutical Statistics, 2008, 7, 155-157.	1.3	0
80	A century of T-tests. Significance, 2008, 5, 37-39.	0.4	11
81	Thet-test tool. Significance, 2008, 5, 40-41.	0.4	4
82	Editorial/Letters. Significance, 2008, 5, 92-93.	0.4	1
83	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554.	27.0	1,969
84	Bronchodilation of formoterol administered with budesonide: Device and formulation effects. Contemporary Clinical Trials, 2008, 29, 114-124.	1.8	13
85	A Note Concerning a Selection â€œParadoxâ€•of Dawid's. American Statistician, 2008, 62, 206-210.	1.6	40
86	Transposed Conditionals, Shrinkage, and Direct and Indirect Unbiasedness. Epidemiology, 2008, 19, 652-654.	2.7	12
87	Comment on article by Gelman. Bayesian Analysis, 2008, 3, .	3.0	26
88	Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates. Pediatrics, 2007, 120, 1224-1225.	2.1	1
89	Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics, 2007, 6, 161-170.	1.3	90
90	Trying to be precise about vagueness. Statistics in Medicine, 2007, 26, 1417-1430.	1.6	99

#	Article	IF	Citations
91	Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. Statistics in Medicine, 2007, 26, 5529-5544.	1.6	69
92	Statistical issues in first-in-man studies. Journal of the Royal Statistical Society Series A: Statistics in Society, 2007, 170, 517-579.	1.1	40
93	Safety first?. Significance, 2007, 4, 79-80.	0.4	2
94	Drawbacks to Noninteger Scoring for Ordered Categorical Data. Biometrics, 2007, 63, 296-298.	1.4	11
95	Probabilistic index: an intuitive non-parametric approach to measuring the size of the treatment effects by L. Acion, J. J. Peterson, S. Temple and S. Arndt,Statistics in Medicine 2006;25(4):591â€“602. Statistics in Medicine, 2006, 25, 3944-3946.	1.6	14
96	Change from baseline and analysis of covariance revisited. Statistics in Medicine, 2006, 25, 4334-4344.	1.6	267
97	Cross-over trials in Statistics in Medicine : the first â€˜25â€™ years. Statistics in Medicine, 2006, 25, 3430-3442.	1.6	81
98	Sharp tongues and bitter pills. Significance, 2006, 3, 123-125.	0.4	2
99	Epigenetics or ephemeral genetics?. European Journal of Human Genetics, 2006, 14, 1149-1149.	2.8	10
100	An Early â€œAtkins' Dietâ€• RA Fisher Analyses a Medical â€œExperimentâ€• Biometrical Journal, 2006, 48, 193-204.	1.0	3
101	Early piribedil monotherapy of Parkinson's disease: A planned sevenâ€month report of the REGAIN study. Movement Disorders, 2006, 21, 2110-2115.	3.9	61
102	JAMA's policy does not go far enough. BMJ: British Medical Journal, 2006, 332, 305.2.	2.3	2
103	Analysis: Repeated Measures in Clinical Trials: Simple Strategies for Analysis Using Summary Measures. , 2005, , 379-395.		0
104	â€˜Equivalence is Differentâ€™ â€“ Some Comments on Therapeutic Equivalence. Biometrical Journal, 2005, 47, 104-107.	1.0	11
105	An unreasonable prejudice against modelling?. Pharmaceutical Statistics, 2005, 4, 87-89.	1.3	14
106	Misunderstandings regarding clinical cross-over trials. Statistics in Medicine, 2005, 24, 3675-3678.	1.6	6
107	Bitter Pills and Puffed Trials. PLoS Medicine, 2005, 2, e219.	8.4	2
108	When is a drug not a drug?. Significance, 2004, 1, 159-161.	0.4	1

#	Article	IF	Citations
109	Controversies concerning randomization and additivity in clinical trials. Statistics in Medicine, 2004, 23, 3729-3753.	1.6	109
110	The analysis of the AB/BA cross-over trial in the medical literature. Pharmaceutical Statistics, 2004, 3, 123-131.	1.3	6
111	Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence. Pharmaceutical Statistics, 2004, 3, 133-142.	1.3	37
112	Individual response to treatment: is it a valid assumption?. BMJ: British Medical Journal, 2004, 329, 966-968.	2.3	130
113	Turning a blind eye: Authors have blinkered view of blinding. BMJ: British Medical Journal, 2004, 328, 1135.3-1136.	2.3	18
114	JOHN NELDER: FROM GENERAL BALANCE TO GENERALISED MODELS (BOTH LINEAR AND HIERARCHICAL). , 2004, , 1-11.		3
115	Lost opportunities for statistics. Pharmaceutical Statistics, 2003, 2, 3-4.	1.3	3
116	Examples of option values in drug development. Pharmaceutical Statistics, 2003, 2, 113-125.	1.3	18
117	Disappointing dichotomies. Pharmaceutical Statistics, 2003, 2, 239-240.	1.3	82
118	A note on non-parametric ANCOVA for covariate adjustment in randomized clinical trials. Statistics in Medicine, 2003, 22, 3583-3596.	1.6	31
119	Editorial: Pharmaceuticals, patents and competition-some statistical issues. Journal of the Royal Statistical Society Series A: Statistics in Society, 2003, 166, 271-274.	1.1	4
120	Foreword: A blue plaque for Fisher. Journal of the Royal Statistical Society: Series D (the Statistician), 2003, 52, 297-298.	0.2	1
121	A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clinical Therapeutics, 2003, 25, 1295-1320.	2.5	163
122	A Conversation with John Nelder. Statistical Science, 2003, 18, 118.	2.8	9
123	Competing interests. BMJ: British Medical Journal, 2003, 326, 883-883.	2.3	2
124	Ethics of clinical trials from bayesian perspective: Society's role is important. BMJ: British Medical Journal, 2003, 326, 1456-b-1457.	2.3	3
125	Ethical considerations concerning treatment allocation in drug development trials. Statistical Methods in Medical Research, 2002, 11, 403-411.	1.5	34
126	The Unpleasant Placebo?. Chance, 2002, 15, 27-29.	0.2	0

#	Article	IF	Citations
127	A comment on replication,p-values and evidence S.N.Goodman,Statistics in Medicine 1992;11:875-879. Statistics in Medicine, 2002, 21, 2437-2444.	1.6	70
128	Authorship of drug industry trials. Pharmaceutical Statistics, 2002, 1, 5-7.	1.3	7
129	Power is indeed irrelevant in interpreting completed studies. BMJ, The, 2002, 325, 1304.	6.0	10
130	Screening for breast cancer with mammography. Lancet, The, 2001, 358, 2165.	13.7	17
131	Cross-over trials in drug development: theory and practice. Journal of Statistical Planning and Inference, 2001, 96, 29-40.	0.6	9
132	Surveillance of antimicrobial resistance â€" what, how and whither?. Clinical Microbiology and Infection, 2001, 7, 316-325.	6.0	117
133	Statistical issues in bioequivalance. Statistics in Medicine, 2001, 20, 2785-2799.	1.6	53
134	Two cheers for P-values?. Journal of Epidemiology and Biostatistics, 2001, 6, 193-204.	0.4	88
135	Repeated measures in clinical trials: simple strategies for analysis using summary measures. , 2000, 19, 861-877.		102
136	Consensus and Controversy in Pharmaceutical Statistics. Journal of the Royal Statistical Society: Series D (the Statistician), 2000, 49, 135-176.	0.2	71
137	Letter to the editor. Contemporary Clinical Trials, 2000, 21, 589-592.	1.9	7
138	Screening mammography re-evaluated. Lancet, The, 2000, 355, 750.	13.7	10
139	Letters to the editor. Annals of Allergy, Asthma and Immunology, 2000, 84, 639.	1.0	8
140	Clinical cross-over trials in phase I. Statistical Methods in Medical Research, 1999, 8, 263-278.	1.5	16
141	A Comment on Optimal Allocations for Bioequivalence Studies. Biometrics, 1999, 55, 1314-1315.	1.4	4
142	Investigating underlying risk as a source of heterogeneity in meta-analysis by S. G. Thompson, T. C. Smith and S. J. Sharp,Statistics in Medicine,16, 2741-2758 (1997). , 1999, 18, 110-115.		29
143	Preface. , 1999, 18, 1739-1739.		1
144	Investigating underlying risk as a source of heterogeneity in metaâ€analysis by S. G. Thompson, T. C. Smith and S. J. Sharp, Statistics in Medicine, 16, 2741â€"2758 (1997). Statistics in Medicine, 1999, 18, 110-115.	1.6	1

#	Article	IF	Citations
145	Mathematics Governess or Handmaiden?. Journal of the Royal Statistical Society: Series D (the) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.2	8
146	Some controversies in planning and analysing multi-centre trials. Statistics in Medicine, 1998, 17, 1753-1765.	1.6	138
147	Robust and realistic approaches to carry-over. , 1998, 17, 2849-2864.		30
148	In the blood: proposed new requirements for registering generic drugs. Lancet, The, 1998, 352, 85-86.	13.7	27
149	Estimating treatment effects in clinical crossover trials. Journal of Biopharmaceutical Statistics, 1998, 8, 191-233.	0.8	27
150	Further Statistical Issues in Project Prioritization in the Pharmaceutical Industry. Drug Information Journal, 1998, 32, 253-259.	0.5	13
151	Some controversies in planning and analysing multi-centre trials. , 1998, 17, 1753.		1
152	Some controversies in planning and analysing multiâ€¢centre trials. Statistics in Medicine, 1998, 17, 1753-1765.	1.6	1
153	Robust and realistic approaches to carryâ€•over. Statistics in Medicine, 1998, 17, 2849-2864.	1.6	1
154	LETTER TO THE EDITOR: Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses, by D. M. Rom and E. Hwang,Statistics in Medicine,15, 1489-1505 (1996). Statistics in Medicine, 1997, 16, 1303-1305.	1.6	22
155	LETTER TO THE EDITOR: The case for cross-over trials in phase III by B. J. Jones and J. Lewis,Statistics in Medicine,14, 1025-1038 (1995). , 1997, 16, 2021-2022.		12
156	A Comment on Interim Analyses in Crossover Trials. Biometrics, 1996, 52, 1515.	1.4	2
157	LETTER TO THE EDITOR INCLUDING AUTHOR'S REPLY: A PERSONAL VIEW OF SOME CONTROVERSIES IN ALLOCATING TREATMENT TO PATIENTS IN CLINICAL TRIALS by Stephen Senn,Statistics in Medicine,14, 2661-2674 (1995). , 1996, 15, 113-116.		0
158	SOME STATISTICAL ISSUES IN PROJECT PRIORITIZATION IN THE PHARMACEUTICAL INDUSTRY. , 1996, 15, 2689-2702.		33
159	Baseline balance and conditional size: a reply to overall Et al. Journal of Biopharmaceutical Statistics, 1996, 6, 201-210.	0.8	2
160	SOME STATISTICAL ISSUES IN PROJECT PRIORITIZATION IN THE PHARMACEUTICAL INDUSTRY. Statistics in Medicine, 1996, 15, 2689-2702.	1.6	0
161	In defence of analysis of covariance: A reply to Chambless and Roeback. Statistics in Medicine, 1995, 14, 2283-2285.	1.6	17
162	A personal view of some controversies in allocating treatment to patients in clinical trials. Statistics in Medicine, 1995, 14, 2661-2674.	1.6	46

#	Article	IF	Citations
163	Caution in interpretation needed. BMJ: British Medical Journal, 1995, 310, 667-667.	2.3	13
164	The AB/BA crossover: past, present and future?. Statistical Methods in Medical Research, 1994, 3, 303-324.	1.5	57
165	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Statistics in Medicine, 1994, 13, 197-198.	1.6	176
166	Fisher's game with the devil. Statistics in Medicine, 1994, 13, 217-230.	1.6	71
167	Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Statistics in Medicine, 1994, 13, 293-296.	1.6	61
168	The first t-test. Statistics in Medicine, 1994, 13, 785-803.	1.6	42
169	Regression to the mean and crossover trials revisited. Statistics in Medicine, 1994, 13, 1181-1186.	1.6	2
170	Testing for baseline balance in clinical trials. Statistics in Medicine, 1994, 13, 1715-1726.	1.6	393
171	Methods for assessing difference between groups in change when initial measurement is subject to intra-individual variation. Statistics in Medicine, 1994, 13, 2280-2285.	1.6	24
172	A Comment on CHI, E. M., 1992: Analysis of cross-over trials when within-subject errors follow an AR(1) process. Biom. J. 34, 359â€“365. Biometrical Journal, 1994, 36, 125-128.	1.0	1
173	Regression toward the mean in 2 Ã— 2 crossover designs with baseline measurements. Statistics in Medicine, 1993, 12, 1086-1087.	1.6	1
174	A random effects model for ordinal responses from a crossover trial. by F. Ezzet and J. Whitehead, . Statistics in Medicine, 1993, 12, 2147-2151.	1.6	13
175	Inherent difficulties with active control equivalence studies. Statistics in Medicine, 1993, 12, 2367-2375.	1.6	41
176	Suspended judgment n-of-1 trials. Contemporary Clinical Trials, 1993, 14, 1-5.	1.9	21
177	Baseline distribution and conditional size. Journal of Biopharmaceutical Statistics, 1993, 3, 265-270.	0.8	7
178	Is the â€˜simple carry-overâ€™ model useful?. Statistics in Medicine, 1992, 11, 715-726.	1.6	71
179	Problems with the two stage analysis of crossover trials [letter; comment]. British Journal of Clinical Pharmacology, 1991, 32, 133-711.	2.4	22
180	Crossover trials, degrees of freedom, the carryover problem and its dual. Statistics in Medicine, 1991, 10, 1361-1374.	1.6	34

#	Article	IF	Citations
181	Falsificationism and clinical trials. Statistics in Medicine, 1991, 10, 1679-1692.	1.6	77
182	Covariance analysis in generalized linear measurement error models. Statistics in Medicine, 1990, 9, 583-586.	1.6	7
183	The graphical representation of clinical trials with particular reference to measurements over time. Statistics in Medicine, 1990, 9, 1287-1302.	1.6	36
184	Regression: A New Mode for an Old Meaning?. American Statistician, 1990, 44, 181.	1.6	11
185	Covariate imbalance and random allocation in clinical trials. Statistics in Medicine, 1989, 8, 467-475.	1.6	240
186	The use of baselines in clinical trials of bronchodilators. Statistics in Medicine, 1989, 8, 1339-1350.	1.6	51
187	Combining Outcome Measures: Statistical Power Is Irrelevant. Biometrics, 1989, 45, 1027.	1.4	14
188	Maximum likelihood estimation of treatment effects for samples subject to cregression to the mean. Communications in Statistics - Theory and Methods, 1989, 18, 3389-3406.	1.0	19
189	Cross-over trials, carry-over effects and the art of self-delusion. Statistics in Medicine, 1988, 7, 1099-1101.	1.6	54
190	A Note Concerning the Analysis of an Epidemic of Q Fever. International Journal of Epidemiology, 1988, 17, 891-893.	1.9	6
191	Sober view of AIDS. Nature, 1987, 328, 10-10.	27.8	1
192	Estimating Treatment Effects in Clinical Trials Subject to Regression to the Mean. Biometrics, 1985, 41, 555.	1.4	42
193	Intention to Treat, Missing Data and Related Matters. , 0, , 165-181.		0
194	One-Sided and Two-Sided Tests and other Issues to Do with Significance andP-Values. , 0, , 183-193.		2
195	Design and Interpretation of Clinical Trials as Seen by a Statistician. , 0, , 27-42.		1
196	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 0, 7, 30.	1.6	7
197	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 0, 7, 30.	1.6	8
198	Misunderstanding publication bias: editors are not blameless after allÂ. F1000Research, 0, , .	1.6	1

#	Article	IF	Citations
199	Modelling in Radioactive Waste Disposal. , 0, , 173-185.		0
200	The Work of the Pharmaceutical Statistician. , 0, , 55-66.		1
201	Multiplicity. , 0, , 149-164.		0
202	Determining the Sample Size. , 0, , 195-212.		6
203	Multicentre Trials. , 0, , 213-233.		0
204	Active Control Equivalence Studies. , 0, , 235-250.		0
205	Cross-over Trials. , 0, , 273-285.		7
206	n-of-1 Trials. , 0, , 287-294.		0
207	Sequential Trials. , 0, , 295-315.		0
208	A Brief and Superficial History of Statistics for Drug Developers. , 0, , 9-25.		0
209	Dose-Finding. , 0, , 317-336.		0
210	Concerning Pharmacokinetics and Pharmacodynamics. , 0, , 337-360.		0
211	Bioequivalence Studies. , 0, , 361-381.		0
212	Safety Data, Harms, Drug Monitoring and Pharmaco-Epidemiology. , 0, , 383-404.		0
213	Pharmaco-Economics and Portfolio Management. , 0, , 405-431.		0
214	Concerning Pharmacogenetics, Pharmacogenomics and Related Matters. , 0, , 433-452.		0
215	Probability, Bayes,P-Values, Tests of Hypotheses and Confidence Intervals. , 0, , 43-53.		0
216	Allocating Treatments to Patients in Clinical Trials. , 0, , 67-93.		0

#	Article	IF	Citations
217	The Measurement of Treatment Effects. , 0, , 113-131.		0
218	Demographic Subgroups: Representation and Analysis. , 0, , 133-148.		0
219	Statistics in Practice. , 0, , 499-500.		0